Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Aarti Drugs Ltd. is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. They manufacture drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. Their product list includes active pharmaceuticals ingredients (API) and steroids , pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine, Speciality Chemicals such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N-ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more. R&D programs of the company is focused on new products amongest non-steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on agro chemicals.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Palghar, Maharashtra
- Chairman
- Chandrakant V Gogri
- CEO & MD
- Prakash M Patil
- Registrar
- Link Intime India Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE767A01016
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Aarti Drugs Ltd today?
Aarti Drugs Ltd (AARTIDRUGS) is trading at ₹374.9. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is AARTIDRUGS’s P/E ratio versus the sector?
AARTIDRUGS trades at a P/E of 22.6. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is AARTIDRUGS’s dividend yield?
AARTIDRUGS has a dividend yield of 0.47%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is AARTIDRUGS’s 52-week high and low?
AARTIDRUGS has traded between ₹318.95 and ₹534 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Aarti Drugs Ltd?
Aarti Drugs Ltd has a market capitalisation of ₹3,914 crore.
▶What is AARTIDRUGS’s return on equity?
AARTIDRUGS reports a return on equity of 12.7%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are AARTIDRUGS’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is AARTIDRUGS’s promoter holding?
Promoters hold 54.43% of AARTIDRUGS. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include AARTIDRUGS?
Index membership is listed in the Context block on this page, along with the weight AARTIDRUGS carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Aarti Drugs Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from AARTIDRUGS’s own numbers. The judgement is yours.
AARTIDRUGS at a glance
Aarti Drugs Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Aarti Drugs Ltd (AARTIDRUGS) last traded at ₹374.9, giving it a market capitalisation of ₹3,914 crore. The 52-week range is ₹318.95 to ₹534, and the price is 26% of the way up that range. It trades at a price-to-earnings ratio of 22.6. Promoters hold 54.43% of the company in the latest shareholding filing.
| Market cap | ₹3,914 crore |
|---|---|
| P/E | 22.6 |
| ROE | 12.7% |
| ROCE | 11.7% |